

Ref. No: 306280921
From: Commercial
Date: 28/09/21
Subject: Anti-VEGF treatments for eye conditions

REQUEST

I am analysing the usage of anti-VEGF treatments for eye conditions. I would greatly appreciate if you could answer the following questions:

1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatments:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

3. Within your trust, how many intra-vitreous injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

RESPONSE

Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions. Under section 12 of the Freedom of Information Act the Department is not obliged to comply with your request and we will not be processing your request further.